-+ 0.00%
-+ 0.00%
-+ 0.00%

PRAXIS PRECISION MEDICINES INC: FDA AGREED TO PROPOSED CHANGES TO EMBRAVE3 TRIAL DESIGN TO BE A SINGLE-ARM, BASELINE-CONTROLLED STUDY

路透·12/09/2025 21:01:21

登錄查看新聞詳情